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Abstract
Background: Molecular studies suggest inhibition of colorectal mucosal polyamines (PAs) may be a promising
approach to prevent colorectal cancer (CRC). Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine
(DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of
normal mucosal PAs. In a clinical trial, this combination (compared with placebo) reduced the 3-year incidence of
subsequent high-risk adenomas by >90 %. Familial Adenomatous Polyposis (FAP) is characterized by marked
up-regulation of ODC in normal intestinal epithelial and adenoma tissue, and therefore PA reduction might
be a potential strategy to control progression of FAP-related intestinal polyposis. CPP FAP-310, a randomized,
double-blind, Phase III trial was designed to examine the safety and efficacy of sulindac and DFMO (alone or in
combination) for preventing a clinically relevant FAP-related progression event in individuals with FAP.
Methods: Eligible adults with FAP will be randomized to: CPP-1X 750 mg and sulindac 150 mg, CPP-1X placebo and
sulindac 150 mg, or CPP-1X 750 mg and sulindac placebo once daily for 24 months. Patients will be stratified based on
time-to-event prognosis into one of the three treatment arms: best (ie, longest time to first FAP-related event [rectal/pouch
polyposis]), intermediate (duodenal polyposis) and worst (pre-colectomy). Stage-specific, “delayed time to” FAP-related
events are the primary endpoints. Change in polyp burden (upper and/or lower intestine) is a key secondary endpoint.
Discussion: The trial is ongoing. As of February 1, 2016, 214 individuals have been screened; 138 eligible subjects
have been randomized to three treatment groups at 15 North American sites and 6 European sites. By disease strata,
26, 80 and 32 patients are included for assessment of polyp burden in the rectum/pouch, duodenal polyposis and
pre-colectomy groups, respectively. Median age is 40 years; 59 % are men. The most common reasons for screening
failure include minimal polyp burden (n = 22), withdrawal of consent (n = 9) and extensive polyposis requiring
immediate surgical intervention (n = 9). Enrollment is ongoing.
Trial registration: This trial is registered at ClinicalTrials.gov (NCT01483144; November 21, 2011) and the EU
Clinical Trials Register(EudraCT 2012-000427-41; May 15, 2014).
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Background
Familial adenomatous polyposis (FAP) is a rare, inherited
gastrointestinal (GI) disorder caused by a mutation in the
Adenomatous Polyposis Coli (APC) tumor-suppressor
gene, located on chromosome 5q21-22 [1]. FAP is charac-
terized by the early onset, usually in adolescence, and
gradual development of hundreds to thousands of aden-
omatous polyps in the colon, rectum and duodenum [2].
If left untreated there is a nearly 100 % risk of colorectal
with an average age of diagnosis of 39 years [3–5].
Prophylactic surgery in young adults, including total
colectomy with ileo -rectal anastomosis (IRA), is the
mainstay of treatment and mitigates the development of
colorectal cancer in most patients. Individuals with ex-
tensive rectal involvement usually undergo total procto-
colectomy with ileal-pouch anal anastomosis (IPAA) [3].
Many such patients develop progressive polyposis in the
retained rectum [6, 7] or ileal pouch [8–10]. Despite
excision of the main at-risk organ(s), many patients
develop duodenal adenomas and require frequent sur-
veillance and endoscopic or surgical intervention [11].
This is particularly problematic in patients with mesen-
teric desmoids disease. After colectomy, the main causes
of morbidity and mortality in FAP are duodenal cancer
and desmoid disease. Thus, there is an ongoing unmet
need for an effective chemo-preventive option.
The APC gene suppresses the transcription of several
oncogenes, including MYC, which in turn, regulates the
expression of ornithine decarboxylase (ODC). In patients
with FAP, ODC enzyme activity and polyamine (PA)
levels are markedly increased in the normal colonic mu-
cosa relative to genotype negative family members [12].
Therefore, PA reduction might be a potential strategy
to control the progression of FAP-related colorectal
polyposis, and findings from molecular studies provide
support for this hypothesis [13] (Fig. 1). In a mouse
model of FAP, the combination of eflornithine (difluor-
omethylornithine [DFMO], CPP-1X) and sulindac or
celecoxib non-steroidal anti-inflammatory drugs
(NSAIDs) led to marked reductions in intestinal tumors
compared to each agent alone. Only the DFMO and
sulindac combination reduced total intestinal PA con-
tents [14].
This Phase III, 2-year treatment trial is designed to evalu-
ate the efficacy of a novel combination therapy in patients
with FAP using clinically relevant outcomes such as delay
in FAP-related excisional intervention involving the colon,
rectum pouch and/or duodenum or delay in progression
to more advanced duodenal polyposis, cancer or death.
Methods/Design
Study objectives
The primary objective of this study is to determine
whether CPP-1X/sulindac combination therapy is
superior to either given as monotherapy for 24 months
among patients with FAP. Clinical benefit is defined as a
delay in the time to the first FAP-related disease pro-
gression event with combination therapy versus
monotherapy.
Study design
CPP FAP-310 is an ongoing, randomized, double-blind,
active-controlled, Phase III trial evaluating the efficacy
and safety of CPP-1X/sulindac combination therapy ver-
sus each as monotherapy during a 24-month treatment
period among individuals with FAP [15]. Patients are
assessed endoscopically every 6 months for evidence of
polyposis progression (vide infra).
Participating centers
CPP FAP-310 is being conducted at 15 sites in North
America and 6 sites in Europe. North American sites
include the Cleveland Clinic in Ohio and Florida, Uni-
versity of Utah, Mount Sinai Hospital and University
Health Network in Ontario, Canada, MD Anderson
Cancer Center in Texas, Dana Farber Cancer Institute
in Massachusetts, Mayo Clinic in Minnesota, University
of Michigan, Washington University School of Medicine,
University of Pennsylvania, University of Washington,
University of California San Diego, Emory University in
Georgia, University of Wisconsin-Madison and Vanderbilt
University in Tennessee.
European sites include the Academic Medical Centre
in The Netherlands; University of Bonn Hospital in
Germany; Institut de Malalties Digestive in Spain; Institute
of Genetic Medicine, Newcastle and the Manchester
Centre for Genomic Medicine, University of Manchester
in the United Kingdom and Leuven Cancer Institute in
Belgium.
Study population
Eligible participants (aged ≥18 y) must have a docu-
mented, genotyped adenomatous polyposis coli (APC)
mutation associated with the classic FAP phenotype,
which is typically characterized by an autosomal dominant
pattern of inheritance, onset in adolescence, >100 colorec-
tal adenomas, and 100 % risk for CRC [5]. This includes
participants with intact colons/rectums being considered
for prophylactic surgery, those with IRA or IPAA Inter-
national Society for Gastrointestinal Hereditary Tumours
[InSiGHT] stage 1, 2 or 3 polyposis in the retained rec-
tum or pouch ≥3 years before enrollment, and partici-
pants with duodenal polyposis, Spigelman Stage 3 or 4
(Table 1; Fig. 2). The modified version of the Spigel-
man Staging System is provided in Table 2.
Key exclusion criteria include significant cardiovas-
cular risk factors (uncontrolled high blood pressure,
unstable angina, history of myocardial infarction,
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uncontrolled hyperlipidemia) and clinically significant
hearing loss requiring the use of a hearing aid. A full
listing of the inclusion and exclusion criteria is provided
in the Additional file 1.
Primary outcome measure
The primary efficacy endpoint is the time to first occur-
rence of any FAP-related event in the patient as a whole
(more than one site may be at risk). This includes: (1)
FAP-related excisional intervention involving the colon,
rectum, pouch, duodenum and/or (2) clinically important
events that include progression to more advanced duo-
denal polyposis (Stage 2–4), cancer, or death. Excisional
interventions include surgery or advanced endoscopic
procedures. Definitions for FAP-related disease progres-
sion by patient stratum are provided in Table 3.
Secondary outcome measures
Secondary endpoints include the evaluation of potential
effect-modifying properties of the presence or absence of
an ODC polymorphism and the pharmacokinetics, tissue
and dietary levels, and urinary excretion of PAs. Treat-
ment effects on health-related quality of life (HRQoL)
will be assessed using the patient-reported EORTC core
questionnaire (QLQ C30) [16], GI-specific module of
EORTC questionnaire (QLQ CR29) [17], the EuroQol
EQ-5D [18, 19] and a modified version of the Cancer
Worry Scale [20]. These instruments will be administered
at baseline and at 3, 6, 12, 18 and 24 months post-
enrollment/end of treatment.
Treatment, procedures and assessments
A total of 150 eligible patients will be randomized (1:1:1)
to one of three treatment groups: (1) CPP-1X 750 mg
with sulindac 150 mg, (2) CPP-1X placebo with sulindac
150 mg, and (3) CPP-1X 750 mg with sulindac placebo.
Study drugs are taken orally, once daily as four tablets
(three 250-mg CPP-1X/CPP-1X placebo tablets and one
150-mg sulindac/sulindac placebo tablet). For all ran-
domized patients, treatment will continue for 24 months,
or until the occurrence of an FAP-related event, as defined
in Table 3.
Patients will undergo upper and lower GI endoscopy
every 6 months using standard sedation according to
local clinical management procedures. Endoscopies are
videotaped, with key still photographs, which are de-
Table 1 Patient stratification: eligibility criteria
Patient stratum Description of criteria
Pre-colectomy (Fig. 2a) • Patients with an intact colon/rectum considering prophylactic surgery
Retained rectum/ileal
pouch polyposis (Fig. 2b)
• Patients with ≥3 years since colectomy with IRA/proctocolectomy with pouch and demonstrating polyposis as
defined by Stage 1, 2, 3a:
− Stage 1: 10–25 polyps, all <5 mm
− Stage 2: 10–25 polyps, at least one >1 cm
− Stage 3: >25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any previous
evidence of high-grade dysplasia, even if completely removed
• For all patients, any rectal/pouch polyps >5 mm must be excised at baseline
Duodenal polyposis
(Fig. 2c)
• Patients with ≥1 of the following:
− Current Spigelman Stage 3 or 4
− Patients who had previous surgical endoscopic intervention ≤6 months for Spigelman Stage 3/4 that may have
been down-staged to Spigelman 1/2
aInSiGHT 2011 Staging System (InSiGHT Meeting, 2011, San Antonio, TX)
Fig. 1 CPP-1/sulindac downregulates PAs via dual MoA: CPP-1X decreases PA synthesis by blocking ODC1, and sulindac increases PA catabolism
and export by upregulating transport genes (PPARγ and SAT). MoA, mechanism of action; ODC1, ornithine decarboxylase; PA, polyamine; PPAR,
peroxisome proliferator activated receptor; SAT, sialic acid transport
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identified and stored for subsequent review. A forward-
viewing endoscope will be used to perform three spiral
passes from the third portion of the duodenum to the
duodenal bulb including a side-viewing duodenoscopy to
visualize the papilla, and from the top of the ileal pouch
or ileo-rectal anastomosis to the anal verge. In patients
with an intact colon, a single spiral pass from the cecum
to the anal verge will be performed. All videos include a
standard 2.4-mm endoscopic biopsy forceps in the field of
view. Baseline biopsies are obtained for duodenum staging
(Spigelman scoring), and in the rectum, pouch or colon,
biopsies are obtained for research purposes and for the re-
moval of concerning adenomas. Medications and patient
diaries are provided to participants every 3 months. In the
diaries, patients are instructed to record medication use,
presence of symptoms, and self-assessment of bleeding or
melena. A detailed schedule of study visits and follow-up
is included in the study protocol and clinical trial registry
records [15].
Safety and tolerability
Adverse events (AEs) and adverse drug reactions (ADRs)
will be monitored. AEs are defined as any untoward
medical occurrence regardless of its relationship to study
medication. Serious adverse events (SAEs) include death,
a life-threatening event, hospitalization or prolonged
hospitalization, persistent or significant disability, con-
genital abnormality/birth defect, and any event that
may jeopardize the patient’s well-being. ADRs are events
judged to be related to study medication. AE and SAE
reporting and grading will be performed using the Na-
tional Cancer Institute’s Common Terminology Criteria
for Adverse Events (CTCAE) Version 4.0 [21]. Laboratory
results, including hematology, chemistry and urinalysis,
will be compared over time (ie, screening; months 3, 6, 12
and 18; and end of treatment) to detect any safety signals.
Patients will be followed for safety from start of treatment
through 30 days after treatment discontinuation. Serious
adverse events (SAEs) will be followed until they are re-
solved or return to baseline values.
Adverse events of special interest
To assess cardiac risk, patients will undergo ECG evalu-
ation at baseline and at months 3, 6, 12, 18 and 24. To
assess ototoxicity risk, all patients will undergo air con-
duction audiometry at screening and at months 12 and
24. To assess gastrointestinal risk, patients will conduct
stool assessments and record the findings in their diaries.
Statistical analysis
CPP FAP-310 is a superiority trial, designed to detect a
delay in the primary efficacy endpoint in favor of CPP-1X
and sulindac combination therapy compared with either
as monotherapy.
Sample size
Sample size determination was based on limited data
from CPP-1X and sulindac monotherapy studies in
which the 2-year event-free rates implied a single, overall
event-free rate of 60 % for the combination therapy
group and 30 % for each monotherapy group. Several
assumptions have been made. Statistical analysis will in-
volve two-sided log-rank tests (α = 0.05) for the time to
first FAP-related event for two between-group
Fig. 2 Endoscopic images of patient strata of polyposis: a pre-colectomy,
b rectal/pouch, and c duodenal (Spigelman stage 3/4)
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comparisons: CPP-1X with sulindac versus CPP-1X and
CPP-1X with sulindac versus sulindac. The time to the
first FAP-related event for either monotherapy group is
expected to be approximately twice that for the combin-
ation therapy group. There will be ≥85 % power to de-
tect an effect of treatment when comparing combination
therapy with either as monotherapy. Finally, the two
monotherapy groups will have the same event rate.
With 50 patients per treatment group and assuming 2-
year time-to-first-FAP-related event rates of 70 % for the
monotherapy groups and 40 % for the combination ther-
apy group, the expected number of patients with an FAP-
related event would be 35 in each of the monotherapy
groups and 20 in the combination therapy group. For the
between-group comparisons, it would be expected that 55
patients (SD 4.74) would have an FAP-related event, cor-
responding to nearly 89 % power. A doubling in event-free
follow-up over 2 years corresponds to the design effect
size, a hazard rate ratio of 0.4243 (ln 0.60)/(ln 0.30).
Data analysis
The primary efficacy analysis will be conducted on the
intent-to-treat (ITT) population, defined as all patients
randomized to study treatment; safety assessments will
be performed on the safety population, which includes
all randomized patients who received ≥1 dose of study
drug. Baseline demographic characteristics will include
age, gender, and race; clinical characteristics will include
disease-related features and laboratory values. Continu-
ous variables will be summarized as means (with SDs) or
medians (with ranges), and categorical variables will be
presented as frequency distributions and percentages.
For the primary, time-to-event analysis, a stratified
log-rank test will be used, and data will be displayed
using the Kaplan-Meier method. If an FAP-related event
occurs, that patient will be recorded as having an observed
or uncensored event and will be considered a treatment
“failure.” Cox proportional hazard regression models will
be used for secondary analyses.
For the between-treatment group comparisons, continu-
ous data will be analyzed using an analysis of covariance,
with baseline value, a binary indicator variable for the two
highest-risk patient strata, and a binary indicator variable
for treatment (combination versus monotherapy) as covar-
iates. Categorical data will be analyzed using chi-square
tests and Cochran-Mantel Haenszel tests to reflect the
stratified randomization. Ordered categorical data will be
analyzed using Kruskal-Wallis nonparametric tests.
For the EORTC QLQ-C30 and QLQ-CR29, each single
item or multi-item subscale scores will be standardized
to a scale of 0–100 by applying a linear transformation.
For HRQoL secondary endpoints, single- or multi-item
subscale scores will be categorized as improved or deterio-
rated if the change from baseline is ≥10 points. For the
EuroQoL EQ-5D, patient preferences (or utilities) will be
assessed by determining preference weights among the
treatment groups for individual health states, and quality-
adjusted survival will be generated by multiplying the uti-
lity value by the amount of time spent in a specified health
state. The modified version of the Cancer Worry Scale will
be administered and scored as previously described [20].
Baseline demographic and clinical characteristics
(interim results)
As of February 1, 2016, 214 individuals have been screened,
and 138 eligible subjects have been randomized to one of
Table 3 Definition of FAP-related disease progression by patient
stratum
Patient stratum Disease progression
Pre-colectomy • ≥25 % increase in polyp burden (number, size)
from baseline
• Presence of large, sessile or ulcerated adenoma
(not amenable to excision)
• High-grade dysplasia
• Large villous adenoma
• In-situ or invasive cancer
Retained rectum/ileal
pouch polyposis
• ≥25 % increase in polyp burden (number, size)
from baseline
• Excisional intervention to remove any
polyp ≥10 mm
• High-grade dysplasia in any polyp
• In-situ or invasive cancer on any biopsy
Duodenal polyposis • Increase in Spigelman Stage (2–4) from baseline
• Need for excisional intervention
• Development of cancer
• Death (endoscopy/intervention related)
Table 2 Modified Spigelman’s Score and Classification [26]
Score
Factor 1 Point 2 Points 3 Points Total Score Stage
Number of polyps 1–4 5–20 >20 0 0
Polyp size, mm 1–4 5–10 >10 1–4 1
Histology Tubulous Tubulovillous Villous 5–6 2
Dysplasia Low grade — High gradea 7–8 3
9–12 4
aAssigned to any epithelium showing nuclear stratification all the way to the tops of the cells and loss of mucin production. It can encompass intraepithelial
carcinoma if the cells are pleomorphic or even cribiformed but still all located above the basement membrane
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the three treatment groups (Fig. 3). The randomized popu-
lation has a median age of 40 years and includes 81 male
and 57 female subjects. The enrollment period to date is
24 months. The most frequent reasons for screen failure
include minimal polyp burden (n = 22), extensive polyposis
requiring immediate surgical intervention (10), withdrawal
of consent (n = 9), abnormal baseline labs (n = 5), and
no APC mutation (n = 2).
To date, 8 SAEs have been reported. Worsening of de-
pression with suicidal ideation (n = 1) and deep vein throm-
bosis (n = 1) have been assessed as being possibly related to
study treatment; severe seasonal migraine (n = 1), post-
polypectomy bleed (n = 1), adhesive small bowel obstruc-
tion (n = 1), lung adenocarcinoma (n = 1), small bowel ileus
(n = 1) and pancreatitis (n = 1) have been assessed as not
being related to study treatment. All subjects experiencing
an SAE were stratified to the duodenal polyposis group.
Discussion
FAP is a rare disease (1/10,000) with multiple, major un-
met medical needs. The current initial standard of care is
prophylactic colectomy or proctocolectomy, followed by
regular and lifelong endoscopic evaluation, polypectomies
or laser/cautery ablation and additional operations. Con-
trolling the progression of colorectal polyposis burden,
minimizing the development of high-grade dysplasia and
avoiding interval cancer would provide patients and
physicians with the ability to prevent or delay prophy-
lactic surgery in younger patients to a more convenient
time. Specific control of rectal polyposis may increase
the likelihood that a colectomy with IRA can be per-
formed as the initial procedure. Bowel function, anal
incontinence and female fecundity may be improved
without the pelvic dissection and ileal pouch required
for proctocolectomy.
Approximately 50 % of patients with retained rectum
or ileal pouch develop adenomatous disease requiring
frequent endoscopies, polypectomies and ablation. Al-
though cancer is infrequent, regular proctoscopies are
inconvenient and increased post-polypectomy scarring
can result in loss of compliance, increased stool fre-
quency and increased fecal urgency.
Patients Screened (N=214)














Minimal polyp burden 22
Extensive polyposis/surgery 10
Withdrew consent 9
Abnormal baseline labs 5
No APC mutation 2
Other 13
EOT
(24 mo [±2 wk])
EOT
(24 mo [±2 wk])
EOT
(24 mo [±2 wk])
30-Day Follow-up
(±1 wk off study)
30-Day Follow-up
(±1 wk off study)
30-Day Follow-up
(±1 wk off study)
2–6 mo Follow-up
(±1 wk off study)
2–6 mo Follow-up
(±1 wk off study)
2–6 mo Follow-up
(±1 wk off study)
In-process Screening (n=15) 
Fig. 3 Flowchart of the study (as of February 1, 2016). *Treatment arm is assigned in double-blinded fashion; exact numbers of randomized
patients per treatment arm are not known. APC, adenomatous polyposis coli; CPP-1X, eflornithine; EOT, end of treatment; PBO, placebo
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Duodenal polyposis occurs in >90 % of patients and
requires regular surveillance. Both advanced or symp-
tomatic ampullary disease and large duodenal polyps
require complex endoscopic and surgical procedures
even in the absence of invasive cancer. This problem
represents the major source of morbidity and prema-
ture mortality in FAP patients.
The CPP FAP-310 trial combines patients with all three
major life-time FAP-related polyposis disease sites: (1)
primary colorectal, (2) retained rectum/ileal pouch, and
(3) advanced duodenal disease. The major objective of
this clinical trial program is to defer or obviate the need
for additional surgical interventions in FAP patients.
Secondarily, the study will determine treatment effects
on HRQoL.
The development of novel pharmacotherapies that ef-
fectively increase the time to FAP-related events are im-
portant for controlling the morbidity and mortality
associated with this genetic disease. Sulindac has been
used “off-label,” particularly to control colorectal polyp-
osis. However, sulindac monotherapy for the treatment
of duodenal polyposis has shown little to no efficacy
[22, 23]. Celecoxib was approved by the FDA in 1999
as an adjunct to endoscopy to treat FAP based on data
from a 6-month trial demonstrating a 28 % reduction
in polyp count in a defined segment of the bowel [24].
However, because regulatory post-market clinical stud-
ies were not completed, and evidence of clinical benefit
was not provided, the indication for FAP was removed
from celecoxib’s product label.
In a study by Lynch and colleagues, the relative efficacy
of combination therapy with DFMO and celecoxib versus
celecoxib monotherapy was evaluated in FAP patients
[25]. In this trial, 112 patients were randomized, but only
68 patients were evaluable at 6 months (ie, baseline and 6-
month endoscopy data for those who took most of their
daily drug dosage by this time point). The study used
three key endpoints. The primary endpoint was polyp
counts in designated areas (“defined anatomic fields”) of
the bowel. Secondary endpoints focused on changes in
polyp burden (number and size) as determined using still
images and video assessments. In the still images, the
number and size of polyps were estimated in the “defined
anatomic fields.” Open and closed forceps were used for
size estimation. In the video assessment, five independent
reviewers evaluated four segments of the colon and rec-
tum, or if post-colectomy, only the rectum. Each segment
was evaluated at 6 months and compared with baseline.
Grades included: much better, better, the same, worse or
much worse.
The primary endpoint data trend supported the benefit
of the combination therapy, but because of the relatively
small sample size, the difference was not statistically sig-
nificant. When comparing polyp counts or burden in
pre-defined areas of still photos, DFMO and celecoxib
combination therapy was not superior to celecoxib
monotherapy. However, when the polyp burden was
assessed for the entire colorectum by multiple reviewers
of blinded video-endoscopy, the DFMO/celecoxib group
showed 93 % improvement and the celecoxib monothe-
rapy group showed 36 % improvement (p = 0.01). Clinical
care and management decisions focus on the entire bowel
polyp burden as well on high-risk adenomas (large and/or
with high grade dysplasia). No data were presented with
regard to high-grade dysplasia.
The Lynch report provided additional support for the
proof-of-principle concept for the current trial; however,
there are important differences in the trial designs. First,
the previous study was short (ie, 6 months) and included
a relatively small number of patients (ie, 68). By contrast,
in the CPP FAP-310 trial, patients are receiving CPP-1X
and sulindac combination therapy for 24 months, which
is critical for determining clinically relevant outcomes.
The target sample size is 150 patients, and nearly 95 %
of this total is currently enrolled. In the previous study,
the primary endpoint of counting polyps in small, desig-
nated areas of the colon is not clinically meaningful. The
secondary endpoint of changes in global polyp burden is
more predictive of clinical benefit.
In the celecoxib registration trial, patients received
200 mg/day or 800 mg/day celecoxib monotherapy,
much higher than the standard NSAID dose. Two pa-
tients in the 800-mg group withdrew from the trial
owing to an allergic reaction and dyspepsia [24]. In the
Lynch report, patients received 800 mg/day celecoxib. In
the celecoxib and placebo group, 20 % (11/55) of patients
reported fatigue, 20 % (11/55) experienced mucositis/
stomatitis; 10 % (6/55) experienced diarrhea and 10 %
(6/55) had nausea/vomiting [25]. In the CPP FAP-310
study, the dose of sulindac is one-half that of a standard
NSAID dose. For safety reasons, the use of low-dose
sulindac is preferred, as the drug regimen is likely to be
used for many years by patients with FAP.
For the CPP FAP-310 trial, the efficacy endpoints are
based on specific input received from regulatory agencies
in the United States and Europe and are focused on pro-
viding “clinically meaningful” results. That is, findings for
which the effects of treatment are large and perceived to
be of benefit from the patient’s perspective. Indeed, avoi-
ding or delaying major excisional interventions as defined
in the FAP-310 trial is clearly meaningful to patients.
In general, the clinical management of FAP is driven
by the progression of polyp burden, resulting in “FAP-re-
lated events,” as specified by these regulatory agencies.
By extension, polyp burden regression is associated with
delaying progression and mitigating FAP-related events.
A delay in the time to colectomy or proctocolectomy is
important to patients. Avoiding major resections of the
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duodenum greatly reduces morbidity and mortality. Pre-
serving bowel function in the retained rectum or ileal
pouch by reducing the need for repeated excisional inter-
ventions is an additional unmet medical need. All of these
will be evaluated in the CPP FAP-310 trial, setting a prece-
dent for the inclusion of more rigorous, clinically relevant
efficacy assessments for this and future FAP trials.
Additional file
Additional file 1: Study protocol inclusion and exclusion criteria.
(DOCX 17 kb)
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